BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17704825)

  • 1. GPR55 and the vascular receptors for cannabinoids.
    Hiley CR; Kaup SS
    Br J Pharmacol; 2007 Nov; 152(5):559-61. PubMed ID: 17704825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
    Mo FM; Offertáler L; Kunos G
    Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
    Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling.
    Su JY; Vo AC
    Eur J Pharmacol; 2007 Mar; 559(2-3):189-95. PubMed ID: 17292352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
    Johns DG; Behm DJ; Walker DJ; Ao Z; Shapland EM; Daniels DA; Riddick M; Dowell S; Staton PC; Green P; Shabon U; Bao W; Aiyar N; Yue TL; Brown AJ; Morrison AD; Douglas SA
    Br J Pharmacol; 2007 Nov; 152(5):825-31. PubMed ID: 17704827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
    McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
    Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.
    MacIntyre J; Dong A; Straiker A; Zhu J; Howlett SE; Bagher A; Denovan-Wright E; Yu DY; Kelly ME
    Eur J Pharmacol; 2014 Jul; 735():105-14. PubMed ID: 24751709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACPA and JWH-133 modulate the vascular tone of superior mesenteric arteries through cannabinoid receptors, BK
    López-Dyck E; Andrade-Urzúa F; Elizalde A; Ferrer-Villada T; Dagnino-Acosta A; Huerta M; Osuna-Calleros Z; Rangel-Sandoval C; Sánchez-Pastor E
    Pharmacol Rep; 2017 Dec; 69(6):1131-1139. PubMed ID: 29128791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Endothelium in Abnormal Cannabidiol-Induced Vasoactivity in Retinal Arterioles.
    Su EN; Kelly ME; Cringle SJ; Yu DY
    Invest Ophthalmol Vis Sci; 2015 Jun; 56(6):4029-37. PubMed ID: 26098470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.
    Li K; Fichna J; Schicho R; Saur D; Bashashati M; Mackie K; Li Y; Zimmer A; Göke B; Sharkey KA; Storr M
    Neuropharmacology; 2013 Aug; 71(100):255-63. PubMed ID: 23603203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The orphan receptor GPR55 is a novel cannabinoid receptor.
    Ryberg E; Larsson N; Sjögren S; Hjorth S; Hermansson NO; Leonova J; Elebring T; Nilsson K; Drmota T; Greasley PJ
    Br J Pharmacol; 2007 Dec; 152(7):1092-101. PubMed ID: 17876302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation.
    Hu G; Ren G; Shi Y
    Oncogene; 2011 Jan; 30(2):139-41. PubMed ID: 21057532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55.
    Schuelert N; McDougall JJ
    Neurosci Lett; 2011 Aug; 500(1):72-6. PubMed ID: 21683763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPR55: a new member of the cannabinoid receptor clan?
    Pertwee RG
    Br J Pharmacol; 2007 Dec; 152(7):984-6. PubMed ID: 17876300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.
    McHugh D; Hu SS; Rimmerman N; Juknat A; Vogel Z; Walker JM; Bradshaw HB
    BMC Neurosci; 2010 Mar; 11():44. PubMed ID: 20346144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery.
    Ho WS; Hiley CR
    J Pharm Pharmacol; 2004 Jul; 56(7):869-75. PubMed ID: 15233865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.